SNGX vs SPRO

Soligenix, Inc. vs Spero Therapeutics, Inc. — Valuation Comparison 2026

SNGX

Biotechnology
Soligenix, Inc.
Quality
5.0
out of 10
Value Trap
35
LOW
Price
$0.97
Last close
Models
9/13
Active
VS

SPRO

Biotechnology
Spero Therapeutics, Inc.
Quality
7.5
out of 10
Value Trap
42
WARN
Price
$2.90
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType SNGX Fair ValueSNGX Upside SPRO Fair ValueSPRO Upside
Bayesian DCF Intrinsic $0.46 -52.8% $1.28 -55.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.74 +78.5% $1.96 -32.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SNGX vs SPRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SNGX vs SPRO — Which Stock Is More Undervalued?

SPRO scores higher with a 7.5/10 quality rating vs SNGX's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Soligenix, Inc. (SNGX) and Spero Therapeutics, Inc. (SPRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SNGX currently trades at $0.97 with a QOC of 5.0/10, while SPRO trades at $2.90 with a QOC of 7.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).